3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
102
Breast Neoplasms
10
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Triple Negative Breast Neoplasms
5
Castration-resistant Prostate Cancer
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
Prostate Cancer Metastatic
2
Prostate Adenocarcinoma
2
Ovarian Neoplasms
2
Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2
Metastatic Castration-Resistant Prostate Cancer
2
Metastatic Castration Resistant Prostate Cancer
2
Castration Resistant Metastatic Prostate Cancer
2
Carcinoma, Hepatocellular
2
Adenocarcinoma of the Prostate
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Thrombocytosis
1
Stomach Neoplasms
1
Solid Tumor
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Interventions
etoposide phosphate
1
enzalutamide
1
Tissue Banks
1
Temozolomide
1
Radiotherapy
1
Radiation
1
Patient Discharge
1
Etoposide
1
Dasatinib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Brain Diseases
×
enzalutamide
×
Clear all
NCT04290611
2023-04-13
VENDY
Groupe Hospitalier Pitie-Salpetriere
Completed
500,000 enrolled